Novus Acquisition and Development Corp (NDEV)

[was GoldenDD]

Nine States with Ballot Initiatives, Marks Emerging Growth

MIAMI, FL / ACCESSWIRE / October 18, 2016 / Novus Acquisition and Development Corp. (OTC Markets: NDEV), the nation's first healthcare insurance carrier in the medical cannabis field and property and casualty sector, provides its status and positioning on the upcoming November 8 state ballots and cannabis healthcare. Novus CEO Frank Labrozzi offers a summary update to the upcoming cannabis state ballots and his view and the company's positioning for the future of cannabis in the United States.

On November 8, less than a month away, marijuana state ballot initiatives are all pointing toward voter approval. These ballot initiatives will likely reshape the cannabis industry in the U.S. with legalization and recreational proposals in Arizona, California, Maine, Massachusetts and Nevada and medical marijuana proposals in Arkansas, Florida, Montana and North Dakota.

According to the Organization for Reform of Marijuana Laws, polls show that approval percentages in Arizona are over 50%, Nevada 57% and California overwhelming 60%, Maine and Massachusetts with over 53%. In fact, a recent September 12, 2016 Cowen and Company Collaborative Insights Report titled, The Cannabis Compendium: Cross-Sector Views on a Budding Industry, believes that California passing recreational has an 80% probability.

Novus shareholders should know that Novus's footprint in the cannabis sector is Washington, Oregon, Arizona, California, Nevada, Colorado and Michigan. Additionally, the states that are up and coming that Novus will be entering into post election are Illinois, Massachusetts, Pennsylvania and Maine. Novus is well-positioned to take advantage of increased legalization of cannabis, both recreational and medical.

If all five state ballot initiatives were to pass, the percentage of U.S. population and GDP captured by recreational states would be 23% and 26%, respectively. A California recreational approval, which is already estimated to be a $1 billion medical marijuana market, would add an approximate 39 million people to the number of Americans living in a state legalized for recreational cannabis, tripling the market in the U.S.

These aforementioned states, the percent of the U.S. population and GDP covered by recreational states would grow expenditally. While Novus' full business potential in legal cannabis space and in the healthcare sector is now well into focus, early indicators suggest that the potential is considerable. Indeed, it is arguably in healthcare that legal cannabis could make its first big crossover to the mainstream marketplace.

Despite the current barriers that hinder the progress of cannabis healthcare what is encouraging is consumer demand for existing medical cannabis products primarily for pain. Giving our government and healthcare professionals comfort to know that is can significantly reduce addiction to, and deaths from, opioid painkillers could bolster cannabis's credibility as a legitimate healthcare product as an opioid replacement.

As full federal legalization maybe some time in the future, policy is already shifting with relaxed restriction coming from the DEA it will now be up to Congress to make cannabis part of the healthcare mainstream. And when this happens, history has shown the one thing that biotechnology and pharmaceuticals have in common is they are always dove tailed within health insurance.

NDEV 2nd Quarter Financial Filing: http://bit.ly/2cJ3Efj
Website: http://www.getnovusnow.com
Investor Relations Website: http://www.getnovusnow.com/ndev/investor_page


About Novus

Novus Acquisition & Development Corp. (NDEV), through its subsidiary WCIG Insurance, provides health insurance and related insurance solutions within the wellness and medical marijuana industries in states where legal programs exist. Novus has positioned itself to gain market share within many lines of insurance business within and outside of the MMJ sector.

Novus will work as outside developers and will not cultivate, handle, transport grow, extract, dispense, put up for sale, put on the market, vend, deliver, supply, circulate, or trade cannabis or any substances that violate the United States law or the Controlled Substances Act, nor does it intend to do so in the future and will continue to follow state and federal laws. The statements made about specific products have not been evaluated by the United States Food and Drug Administration (FDA) and are not intended to diagnose, treat, cure or prevent disease. All information provided on these press releases or any information contained on or in any product label or packaging is for informational purposes only and is not intended as a substitute for advice from your physician or other health care professional. Once a push notification is competed the transaction is solely between the state-licensed dispensary and the registered patient.

The state laws are in conflict with the federal Controlled Substances Act. The current administration has effectively stated that it is not an efficient use of resources to direct federal law enforcement agencies to prosecute those lawfully abiding by state designated laws, allowing the use and distribution of medical marijuana. However, there is no guarantee that the current administration, nor any future administration, will not change this policy and decide to enforce the federal laws strongly. Any such change in the federal government's enforcement of current federal laws could cause significant financial changes to Novus Medical Group. While we do not intend to harvest, distribute or sell cannabis or cannabis related products, we may be harmed by a change in enforcement by federal or state governments.

For more information, check out: http://www.getnovusnow.com
For NDEV 2nd Quarter Financial Filing: http://bit.ly/2cJ3Efj
Learn How Insurance Companies Are Evaluated: http://bit.ly/2ddIYva
Forward-Looking Statements

This release includes forward-looking statements, which are based on certain assumptions and reflects management's current expectations. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. Some of these factors include: general global economic conditions; general industry and market conditions and growth rates; uncertainty as to whether our strategies and business plans will yield the expected benefits; increasing competition; availability and cost of capital; the ability to identify and develop and achieve commercial success; the level of expenditures necessary to maintain and improve the quality of services; changes in the economy; changes in laws and regulations, includes codes and standards, intellectual property rights, and tax matters; or other matters not anticipated; our ability to secure and maintain strategic relationships and distribution agreements. Novus Medical Group disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Contact Information

Corporate:
Chairman and CEO
Frank Labrozzi
[e-mail]
855-228-7355




Investors:
Hayden IR
[e-mail]
917-658-7878



SOURCE: Novus Acquisition and Development Corp.